BridgeBio Oncology Therapeutics, Inc.

NasdaqGM:BBOT Stock Report

Market Cap: US$706.5m

BridgeBio Oncology Therapeutics Management

Management criteria checks 0/4

BridgeBio Oncology Therapeutics' CEO is Pedro Beltran, appointed in Apr 2026, has a tenure of less than a year. directly owns 0.008% of the company’s shares, worth $58.71K. The average tenure of the management team and the board of directors is 0.7 years and 1.1 years respectively.

Key information

Pedro Beltran

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.008%
Management average tenureless than a year
Board average tenure1.1yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 13

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

Summary BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supported by three promising KRAS/RAS-targeted drug candidates. BBOT's lead asset, BB-8520, showed a 65% objective response rate and 100% disease control in KRAS G12C NSCLC, exceeding results from approved competitors. Further mature data readouts for BBOT’s pipeline are expected in 2H26, representing key catalysts for share price re-rating and future funding opportunities. BBOT maintains robust funding into 2028 and has strengthened its management team with experienced oncology leaders, positioning well for upcoming clinical milestones. Read the full article on Seeking Alpha
Analysis Article • Aug 17

We Think BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Can Afford To Drive Business Growth

NasdaqGM:BBOT 1 Year Share Price vs Fair Value Explore BridgeBio Oncology Therapeutics's Fair Values from the Community...

CEO Compensation Analysis

How has Pedro Beltran's remuneration changed compared to BridgeBio Oncology Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$154m

Dec 31 2025n/an/a

-US$134m

Sep 30 2025n/an/a

-US$115m

Jun 30 2025n/an/a

-US$87m

Mar 31 2025n/an/a

-US$81m

Dec 31 2024US$3mUS$517k

-US$74m

Compensation vs Market: Insufficient data to establish whether Pedro's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Pedro's compensation with company performance.

CEO

Pedro Beltran (55 yo)

less than a year
Tenure
US$3,109,284
Compensation

Dr. Pedro J. Beltran, M.D., Ph D., is Chief Executive Officer of BridgeBio Oncology Therapeutics, Inc. from April 20, 2026. and as a member of our board of directors since April 2026.He is Chief Scientifi...

Leadership Team

NamePositionTenureCompensationOwnership
Neil Kumar
Executive Chairman9.9yrsUS$20.00kno data
Frank McCormick
Co-Founderno dataUS$700.35k0%
$ 0
Yong Ben
Chief Medical & Development Officer1.8yrsUS$3.23m0.0083%
$ 58.7k
Pedro Beltran
Chief Executive Officer and Directorless than a yearUS$3.11m0.0083%
$ 58.7k
Marc Cobo
VP of Finance & Controller1.2yrsno data0.00030%
$ 2.1k
Idan Elmelech
Chief Operating Officerless than a yearno data0.00081%
$ 5.7k
Aaron Chan
Vice President of Legalno datano datano data
Bin Wang
Senior Vice President of Drug Discoveryno datano datano data
Daniel Watson
Senior Vice President of Chemistry1.8yrsno datano data
Rui Xu
Senior Vice President of Drug Discoveryno datano datano data
Chunmei Ji
VP & Head of Toxicologyno datano datano data
0.7yrs
Average Tenure
49.5yo
Average Age

Experienced Management: BBOT's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Neil Kumar
Executive Chairman9.9yrsUS$20.00kno data
Frank McCormick
Co-Founder2.2yrsUS$700.35k0%
$ 0
Pedro Beltran
Chief Executive Officer and Directorless than a yearUS$3.11m0.0083%
$ 58.7k
Jacob Bauer
Independent Chairman of the Board1.3yrsUS$934.37k0%
$ 0
Praveen Tipirneni
Independent Director1.7yrsUS$408.27k0%
$ 0
Bihua Chen
Directorless than a yearUS$20.00kno data
Sara A. Hurvitz
Member of Advisory Board1.1yrsno datano data
Peter Lebowitz
Independent Directorless than a yearno data0%
$ 0
Raymond Kelleher
Independent Director2.3yrsUS$22.50kno data
Zev Wainberg
Member of Advisory Board1.1yrsno datano data
Ben Solomon
Member of Advisory Board1.1yrsno datano data
1.1yrs
Average Tenure
58yo
Average Age

Experienced Board: BBOT's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/27 18:51
End of Day Share Price 2026/07/27 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BridgeBio Oncology Therapeutics, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Eric SchmidtCantor Fitzgerald & Co.
Robert BurnsH.C. Wainwright & Co.